Stomach ulcer
Drug research and approvals for stomach ulcer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 34 studies of stomach ulcer are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 34
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- SPADE Clinical Trial.NCT07892183 · Not applicable · National Cancer Center, Korea · starts Jun 25, 2025
- PPI Dosing Per CYP2C19 GenotypeNCT07843264 · Phase 4 · University of Florida · starts Nov 1, 2026
- Preoperative Predictors of Symptom Improvement After Laparoscopic FundoplicationNCT07809620 · Not reported · Minia University · starts Sep 20, 2026
- A Prospective Cohort Study on Endoscopic Features of Upper Gastrointestinal Tract at High Altitude (Zaduo County)NCT07755384 · Not reported · Jilin University · starts Dec 1, 2025
- The Transit Bipartition With the Use of a Metallic Anastomosis Clip and Circular Fundocorporeal GastroplicationNCT07495020 · Not applicable · The Society of Bariatric and Metabolic Surgeons of Kazakhstan · starts Apr 30, 2026
- Efficacy and Safety of Esomeprazole 40 mg IV in Post-Surgical Patients Admitted to the ICUNCT07399054 · Not reported · Asian Institute of Gastroenterology, India · starts Feb 23, 2026
- Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'NCT07385235 · Phase 1 · Addpharma Inc. · starts Jan 27, 2026
- CURE-H. Pylori: A Trial on the Combination of Anti-Ulcerants and Levofloxacin-Based Therapy for Helicobacter Pylori…NCT07344506 · Phase 4 · Dow University of Health Sciences · starts May 1, 2025
- Evaluating the Efficacy of Vonoprazan in Preventing Post-Endoscopic Variceal Band Ligation Ulcers: A Randomized…NCT07267260 · Phase 2 · King Edward Medical University · starts Dec 16, 2025
Approved 7
- LansoprazolePotassium-transporting ATPase inhibitor
- EsomeprazolePotassium-transporting ATPase inhibitor
- OmeprazolePotassium-transporting ATPase inhibitor
- NaproxenCyclooxygenase inhibitor
- RanitidineHistamine H2 receptor antagonist
- MisoprostolProstanoid EP3 receptor agonist
- FamotidineHistamine H2 receptor antagonist
Phase 3 8
- VonoprazanPotassium-transporting ATPase inhibitor
- AspirinCyclooxygenase inhibitor
- Gefarnate
- DiclofenacCyclooxygenase inhibitor
- AmoxicillinBacterial penicillin-binding protein inhibitor
- ClarithromycinBacterial 70S ribosome inhibitor
- TegoprazanPotassium-transporting ATPase blocker
- Rebamipide
Phase 1 or earlier 5
- PantoprazolePotassium-transporting ATPase inhibitor
- LafutidineHistamine H2 receptor antagonist
- Irsogladine
- ATB-346
- PirenzepineMuscarinic acetylcholine receptor M1 antagonist
How its trials ended
105 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 30 whose ending is known, 70% met their primary endpoint, 3% missed it and 27% stopped early.
- Completed, result not reported5350%
- Met its primary endpoint2120%
- Status unknown1413%
- Ongoing88%
- Stopped: enrollment or feasibility44%
- Stopped: other or unclear33%
- Missed its primary endpoint11%
- Stopped: lack of efficacy11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA